RecruitingPhase 1NCT04855435

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

A Phase I Multicentre, Open-label, Dose Escalation Study to Determine the Safety and Preliminary Efficacy of MBS8(1V270) Administered Intravenously to Cancer Patients With Advanced Solid Tumours

Sponsor

MonTa Biosciences ApS

Enrollment

106 participants

Start Date

Apr 12, 2021

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor Cutaneous Melanoma Uveal Melanoma, Metastatic

Summary

The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours. The trial is designed to provide data for further clinical development of MBS8(1V270)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This early-phase study is testing the safety of a new immunotherapy drug called MBS8 (also known as 1V270) in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to activate the immune system to fight cancer. **You may be eligible if...** - You are 18 years or older - You have a confirmed advanced solid tumor that has progressed and no standard treatment is available or you have declined standard treatment - Your tumor can be biopsied - You are willing and able to follow the study schedule **You may NOT be eligible if...** - You are not willing or able to have a tumor biopsy - You are unwilling to comply with study visits and procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.